glp-1 small molecule agonist Oral Small-Molecule Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies A Small-Molecule Oral Agonist of

doi:10.1111/j.1464-5491.2011.03331.x 93

It is critical to understand the difference between compounded and brand-name GLP-1 medications: Brand-name medications (Wegovy, Zepbound) are FDA-approved, manufactured under strict quality controls, and have been tested in large-scale clinical trials Compounded versions are not FDA-approved, meaning they have not undergone the same safety and efficacy testing In 2025, the FDA declared the shortage over, meaning compounding of semaglutide and tirzepatide is no longer legally permitted for most pharmacies Some compounded products have used different salt forms of semaglutide (such as semaglutide acetate instead of semaglutide sodium) that have not been shown to behave identically in the body Who Is a Good Candidate for GLP-1 Weight Loss Medication

Lv YQ, Yuan L, Sun Y, Dou HW, Su JH, Hou ZP, et al

Kothny, W., Lukashevich, V., Foley, J

Moreover, the once-weekly dosing option improves patient compliance compared to daily injections or multiple daily oral medications, marking a significant advancement in diabetes treatment

Additionally, SRY-box transcription factor 9 (Sox9) and Krppel-like factor 4 (Klf4) transcription factors, are Paneth and goblet cell-specific differentiation factors [22, 23]